PHXM Key Statistics, Chart & Performance
The current stock price of PHXM is 3.1 USD. In the past month the price decreased by -29.55%.
PHXM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.67 | 395.31B | ||
| AMGN | AMGEN INC | 15.07 | 177.53B | ||
| GILD | GILEAD SCIENCES INC | 14.68 | 149.20B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.93 | 118.61B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.93 | 84.81B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.37 | 52.44B | ||
| INSM | INSMED INC | N/A | 36.12B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.03 | 27.09B | ||
| INCY | INCYTE CORP | 16.39 | 20.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.47 | 20.99B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.65B |
Related stock screener links
About PHXM
Company Profile
Phaxiam Therapeutics SA is a FR-based company operating in Biotechnology industry. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
Company Info
PHAXIAM Therapeutics SA
60 avenue Rockefeller
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 49
Phone: 33478744438
PHAXIAM Therapeutics SA / PHXM FAQ
What does PHXM do?
Phaxiam Therapeutics SA is a FR-based company operating in Biotechnology industry. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
Can you provide the latest stock price for PHAXIAM Therapeutics SA?
The current stock price of PHXM is 3.1 USD. The price decreased by -0.64% in the last trading session.
Does PHXM stock pay dividends?
PHXM does not pay a dividend.
How is the ChartMill rating for PHAXIAM Therapeutics SA?
PHXM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is PHAXIAM Therapeutics SA (PHXM) stock traded?
PHXM stock is listed on the Nasdaq exchange.
How is the valuation of PHAXIAM Therapeutics SA (PHXM) based on its PE ratio?
PHAXIAM Therapeutics SA (PHXM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.04).
PHXM Technical Analysis
PHXM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHXM. Both the profitability and financial health of PHXM have multiple concerns.
PHXM Financial Highlights
Over the last trailing twelve months PHXM reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 99.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.35% | ||
| ROE | -0.62% | ||
| Debt/Equity | 0.3 |
PHXM Forecast & Estimates
8 analysts have analysed PHXM and the average price target is 10.17 USD. This implies a price increase of 228.04% is expected in the next year compared to the current price of 3.1.
For the next year, analysts expect an EPS growth of 77.73% and a revenue growth -100% for PHXM